Triple-Negative Breast Carcinoma

Surgical Pathology Clinics

Volumn 2, Issue 2, 2009, Pages 247-261

  Livasy, Chad A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like; BRCA1; Breast cancer; Estrogen receptor; Triple negative breast cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM; TAXANE DERIVATIVE;

BREAST CARCINOMA; CARCINOGENESIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSCOPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRIPLE NEGATIVE BREAST CARCINOMA;

EID: 66049153804     PISSN: 18759181     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.path.2009.02.005     Document Type: Review

References (52)

1. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
2. Sorlie T., Perou C., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
3. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
4. Putti T.C., Abd El-Rahim D.M., Rakha E.A., et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18 (2005) 26-35
5. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
6. Gaffey M.J., Mills S.E., Frierson H.F., et al. Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis. Mod Pathol 8 (1995) 31-38
7. Tsuda H., Takarabe T., Hasegawa F., et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24 (2000) 197-202
8. Tsuda H., Takaarabe T., Hasegawa T., et al. Myoepithelial differentiation in high-grade ductal carcinomas with large central acellular zones. Hum Pathol 30 (1999) 1134-1139
9. Foulkes W.E., Brunet J.S., Stefaansson I.M., et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64 (2004) 356-362
10. Vazri S.A., Krumroy L.M., Elson P., et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7 (2001) 1937-1945
11. Foulkes W.D., Stefansson I.M., Chappuis P.O., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95 (2003) 1482-1485
12. Lakhani M., Loman N., Borg A., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11 (2005) 5175-5180
13. Farshid G., Balleine R.L., Cumming M., et al. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol 30 (2006) 1357-1366
14. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers?. Int J Cancer 123 (2008) 236-240
15. Cleator S., Heller W., and Coombes R. Triple-negative breast cancer: therapeutic options. Lancet Oncol 3 (2007) 235-244
16. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9 (2007) R65
17. Nielsen T., Hsu F., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
18. van de Rijn M., Perou C.M., Tibshirani R., et al. Expression of cytokeratins 17 and 5 identifies a group of carcinomas associated with poor clinical outcome. Am J Pathol 161 (2002) 1991-1996
19. Abd El-Rehim D.M., Pinder S.E., Paish C.E., et al. Expression of basal and luminal cytokeratins in human breast carcinoma. J Pathol 203 (2004) 661-671
20. Rodriguez-Pinilla S.M., Sarrio D., Honrado E., et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 60 (2007) 1017-1023
21. Tsuda H., Morita D., Kimura M., et al. Correlation of KIT and EGFR overexpression with invasive ductal carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 96 (2005) 48-53
22. Diaz L.K., Cristofanilli M., Zhou X., et al. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol 18 (2005) 1165-1175
23. Matos I., Dufloth R., Alvarenga M., et al. p63, cytokeratin 5, and P-cadherin: three molecular markers used to distinguish basal phenotype in breast carcinomas. Virchows Arch 447 (2005) 688-694
24. Arnes J.B., Brunet J.S., Stefansson I., et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11 (2005) 4003-4011
25. Ribeiro-Silva A., Ramalho L.N., Garcia S.B., et al. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47 (2005) 458-466
26. Koker M.M., and Kleer C.G. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 28 (2004) 1506-1512
27. Li H., Cherukuri P., Li N., et al. Nestin is expressed in basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 67 (2007) 501-510
28. Reis-Filho J.S., Steele D., Palma S., et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign, and malignant breast tissue. Mod Pathol 19 (2006) 307-319
29. Reis-Filho J.S., Milanezi F., Silva P., et al. Maspin expression in myoepithelial tumors of the breast. Pathol Res Pract 197 (2001) 817-821
30. Moyano J.V., Evans J.R., Chen F., et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 116 (2006) 261-270
31. Pinilla S.M., Honrado E., Hardisson D., et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 99 (2006) 85-90
32. Turner N.C., Reis-Filho J.S., Russell A.M., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26 (2007) 2126-2132
33. Carey L., Perou C., Livasy C., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006) 2492-2502
34. Bauer K., Brown M., Cress R., et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109 (2007) 1721-1728
35. Morris G., Naidu S., Topham A., et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's surveillance, epidemiology, and end results database. Cancer 110 (2007) 876-884
36. Dent R.T.M., Pritchard K.I., Hanna W.M., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13 (2007) 4429-4434
37. Liedtke C., Mazouni C., Hess K., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26 (2008) 1275-1281
38. Smid M., Wang Y., Zhang Y., et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 68 (2008) 3108-3114
39. Heitz F., Harter P., Traut A., et al. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol 26 (2008) [Abstract 1010]
40. Hayes N., Thor A., Dressler L., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357 (2007) 1496-1506
41. Carey L., Dees E., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
42. Rouzier R., Perou C., Symmans W., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
43. Sirohi B., Arnedos M., Popat S., et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19 (2008) 1847-1852
44. Yi S., Uhm J., Cho E., et al. Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. [abstract]. J Clin Oncol 26 (2008)
45. Carey L., Mayer E., Marcom P., et al. TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. [abstract]. Breast Cancer Res Treat 106 (2007)
46. Garber J., Richardson A., Harris L., et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). [abstract]. Breast Cancer Res Treat 100 (2006)
47. O'Shaughnessy J., Weckstein D., Vukelja S., et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. [abstract]. Breast Cancer Res Treat 106 (2007)
48. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. [abstract]. J Clin Oncol 26 (2008)
49. Bryant H., Schultz N., Thomas H., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
50. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
51. Kopetz S., Mita M.M., Mok I., et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. [abstract]. J Clin Oncol 26 (2008)
52. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676